Evaluation of the efficacy and safety of remdesivir in hospitalized patients with a new coronavirus infection COVID-19: data from a Russian university clinic

Introduction. The use of remdesivir in patients with the new coronavirus infection COVID-19 is known to improve the prognosis of the disease. But there is not enough data on efficacy and safety of remdesivir use in patients from Russia.
Aim. To evaluate the efficacy and safety of remdesivir in patients with COVID-19.
Materials and methods. A comparative prospective study was conducted in two parallel groups. The study enrolled 300 patients diagnosed with COVID-19 (grade 1–3 severe pneumonia according to CT scan), who were divided into two groups (n = 150 in each) according to the prescription of remdesivir. Treatment efficacy was assessed by recording cases of disease progression and adverse outcomes. The safety of therapy was assessed by hepatotoxicity and nephrotoxicity.
Results. Patients receiving remdesivir were significantly less likely to be transferred to the intensive care unit (OR 0.3884, 95% CI: 0.1645–0.9175) and to be on artificial ventilation (OR 0.3830, 95% CI: 0.1539–0.9527). Treatment with remdesivir had no significant effect on mortality (OR 0.4932, 95% CI: 0.08897–2.7346) and complications (OR 0.4391, 95% CI: 0.1623–1.1879), including acute respiratory distress syndrome (OR 0.3919, 95% CI: 0.07483–2.0524). The duration of hospitalization was significantly shorter in group 1 patients – 12.2533 days (95% CI: 11.4101–13.0966) compared to group 2 – 14.5267 days (95% CI: 13.5125–15.5408). Hepatotoxicity with remdesivir (OR 1.5376, 95% CI: 0.8035–2.9426), nephrotoxicity (OR 1.6338, 95% CI: 0.522–5.1141) were noted, but no statistically significant difference was found (p > 0.05).
Conclusions. The addition of remdesivir to the basic regimen of patients with new coronavirus infection COVID-19 improved the course of the disease, reducing the risks of patients being transferred to the intensive care unit and of receiving artificial ventilation.

1. Маев И.В., Шпектор А.В., Васильева Е.Ю., Манчуров В.Н., Андреев Д.Н. Новая коронавирусная инфекция COVID-19: экстрапульмональные проявления. Терапевтический архив. 2020;92(8):4–11. https://doi.org/10.26442/00403660.2020.08.000767. Maev I.V., Shpektor A.V., Vasilyeva E.Yu., Manchurov V.N., Andreev D.N. Novel coronavirus infection COVID-19: extrapulmonary manifestations. Terapevticheskii Arkhiv. 2020;92(8):4–11. (In Russ.) https://doi.org/10.26442/00403660.2020.08.000767.

2. Wu Y.C., Chen C.S., Chan Y.J. The outbreak of COVID-19: An overview. J Chin Med Assoc. 2020;83(3):217–220. https://doi.org/10.1097/JCMA.0000000000000270.

3. Ritchie H., Mathieu E., Rodés-Guirao L., Appel C., Giattino C., Ortiz-Ospina E. et al. Coronavirus Pandemic (COVID-19). 2020. Available at: https://ourworldindata.org/coronavirus.

4. Dessie Z.G., Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis. 2021;21(1):855. https://doi.org/10.1186/s12879-021-06536-3.

5. Янушевич О.О., Маев И.В., Крихели Н.И., Левченко О.В., Рогова И.В., Заборовский А.В. и др. Распространенность и прогностическое значение гастроэнтерологических проявлений COVID-19: данные Российской университетской клиники. Терапевтический архив. 2021;93(8):853–861. https://doi.org/10.26442/00403660.2021.08.200977. Tanushevich O.O., Maev I.V., Krikheli N.I., Levchenko O.V., Rogova I.V., Zaborovsky A.V. et al. Prevalence and prognostic value of gastroenterological manifestations of COVID-19: data from the Russian University Clinic. Terapevticheskii Arkhiv. 2021;93(8):853–861. (In Russ.) https://doi.org/10.26442/00403660.2021.08.200977.

6. Gordon C.J., Tchesnokov E.P., Feng J.Y., Porter D.P., Götte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020;295(15):4773–4779. https://doi.org/10.1074/jbc.AC120.013056.

7. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. https://doi.org/10.1038/s41422-020-0282-0.

8. Tanni S.E., Silvinato A., Floriano I., Bacha H.A., Barbosa A.N., Bernardo W.M. Use of remdesivir in patients with COVID-19: a systematic review and meta-analysis. J Bras Pneumol. 2022;48(1):e20210393. https://doi.org/10.36416/1806-3756/e20210393.

9. Pitre T., Van Alstine R., Chick G., Leung G., Mikhail D., Cusano E., et al. Antiviral drug treatment for nonsevere COVID-19: a systematic review and network metaanalysis. CMAJ. 2022;194(28):E969–E980. https://doi.org/10.1503/cmaj.220471.

10. WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet. 2022;399(10339): 1941–1953. https://doi.org/10.1016/S0140-6736(22)00519-0.

11. Авдеев С.Н., Адамян Л.В., Алексеева Е.И., Багненко С.Ф., Баранов А.А., Баранова Н.Н. и др. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19): временные методические рекомендации. Версия 15 (22.02.2022). М.; 2022. 245 с. Режим доступа: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/ВМР_COVID-19_V15.pdf. Avdeev S.N., Adamyan L.V., Alekseeva E.I., Bagnenko S.F., Baranov A.A., Baranova N.N. et al. Prevention, Diagnosis, and Treatment of Novel Coronavirus Infection (COVID-19): Interim Guidelines. Version 15 (02/22/2022). Moscow; 2022. 245 p. (In Russ.) Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/ВМР_COVID-19_V15.pdf.

12. Palacios Cruz M., Santos E., Velázquez Cervantes M.A., León Juárez M. COVID-19, a worldwide public health emergency. Rev Clin Esp (Barc). 2021;221(1):55–61. https://doi.org/10.1016/j.rceng.2020.03.001.

13. Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Postgrad Med J. 2021;97(1147):312–320. https://doi.org/10.1136/postgradmedj-2020-138577.

14. Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–1242. https://doi.org/10.1001/jama.2020.2648.

15. Williamson B.N., Feldmann F., Schwarz B., Meade-White K., Porter D.P., Schulz J. et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature. 2020;585(7824):273–276. https://doi.org/10.1038/s41586-020-2423-5.

16. Ali K., Azher T., Baqi M., Binnie A., Borgia S., Carrier F.M. et al. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. CMAJ. 2022;194(7):E242–E251. https://doi.org/10.1503/cmaj.211698.

17. Zampino R., Mele F., Florio L.L., Bertolino L., Andini R., Galdo M. et al. Liver injury in remdesivir-treated COVID-19 patients. Hepatol Int. 2020;14(5):881–883. https://doi.org/10.1007/s12072-020-10077-3.

18. Grein J., Ohmagari N., Shin D., Diaz G., Asperges E., Castagna A. et al. Compassionate Use of Remdesivir for Patients with Severe COVID-19. N Engl J Med. 2020;382(24):2327–2336. https://doi.org/10.1056/NEJMoa2007016.

19. Wang Y., Zhang D., Du G., Du R., Zhao J., Jin Y. et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578. https://doi.org/10.1016/S0140-6736(20)31022-9.